ChiCTR2000038401 版本V1.2 版本创建时间2020/12/20 22:33:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000038401 

最近更新日期:

Date of Last Refreshed on:

2020-12-20 22:32:02 

注册时间:

Date of Registration:

2020-09-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超声引导下颈浅丛神经阻滞在静脉输液港植入术中的应用

Public title:

Application of ultrasound-guided superficial cervical plexus block in implantation of totally implantable venous access port

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下颈浅丛神经阻滞在静脉输液港植入术中的应用

Scientific title:

Application of ultrasound-guided superficial cervical plexus block in implantation of totally implantable venous access port

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

黄慧梅 

研究负责人:

贺亮 

Applicant:

Huimei Huang 

Study leader:

Liang He 

申请注册联系人电话:

Applicant telephone:

+86 18777358606

研究负责人电话:

Study leader's telephone:

+86 13659633168

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

179543973@qq.com

研究负责人电子邮件:

Study leader's E-mail:

54061799@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广西壮族自治区桂林市乐群路15号

研究负责人通讯地址:

广西壮族自治区桂林市乐群路15号

Applicant address:

15 Lequn Road, Guilin, Guangxi Zhuang Autonomous Region

Study leader's address:

15 Lequn Road, Guilin, Guangxi Zhuang Autonomous Region

申请注册联系人邮政编码:

Applicant postcode:

5410000

研究负责人邮政编码:

Study leader's postcode:

5410000

申请人所在单位:

桂林医学院附属医院

Applicant's institution:

Affiliated Hospital of Guilin Medical University

研究负责人所在单位:

桂林医学院附属医院

Affiliation of the Leader:

Affiliated Hospital of Guilin Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

N/A

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

桂林医学院附属医院伦理委员会

Name of the ethic committee:

Ethical Committee of Affiliated Hospital of Guilin Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-08-05 00:00:00

伦理委员会联系人:

贺亮

Contact Name of the ethic committee:

Liang He

伦理委员会联系地址:

广西壮族自治区桂林市乐群路15号

Contact Address of the ethic committee:

15 Lequn Road, Guilin, Guangxi Zhuang Autonomous Region

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

桂林医学院附属医院

Primary sponsor:

Affiliated Hospital of Guilin Medical University

研究实施负责(组长)单位地址:

广西壮族自治区桂林市乐群路15号

Primary sponsor's address:

15 Lequn Road, Guilin, Guangxi Zhuang Autonomous Region

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广西壮族自治区

市(区县):

桂林

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

Guilin

单位(医院):

桂林医学院附属医院

具体地址:

乐群路15号

Institution
hospital:

Affiliated Hospital of Guilin Medical University

Address:

15 Lequn Road

经费或物资来源:

自筹

Source(s) of funding:

Raise independently

Target disease:

Implantation of totally implantable venous access port

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探讨超声引导下颈浅丛神经阻滞在静脉输液港植入术中的应用是否优于局部麻醉。  

Objectives of Study:

To investigate whether ultrasound-guided superficial cervical plexus block is superior to local anesthesia in implantation of totally implantable venous access port.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、ASA分级Ⅰ~Ⅱ级,女性患者乳腺癌患者。
2、年龄≥18岁且≤65岁。
3、拟行颈内静脉输液港植入手术。
4、无神经阻滞禁忌症:如凝血障碍、阻滞部位局部感染或对局部麻醉药过敏的患者。
5、患者及委托人同意参加本研究,并签署知情同意书。

Inclusion criteria

1. ASA grade I to II,female with breast cancer.
2. The patients aged 18 to 65 years.
3. Scheduled to implantation of totally implantable venous access port in internal jugular vein.
4. Patients have no contraindications to regional blocks such as coagulopathies, local infection at the site of block, or allergy to local anesthetics.
5. The patients and their consignors participate in this study and sign informed consents.

排除标准:

1、因语音障碍不能完成疼痛评分者。
2、既往有精神疾病、酗酒或麻醉品滥用者。
3、预穿刺插管部位有手术、外伤、放射治疗史或血管畸形、闭塞、血栓形成。
4、心功能≥3级;严重肾功能损害(需要肾脏替代治疗);严重肝功能损害(Child-P ugh分级C级);严重的阻塞性和限制性肺疾病的者。

Exclusion criteria:

1. Patients who could not complete the pain score due to speech disorder.
2. Patients with previous psychiatric disorders, alcohol or narcotic abuse.
3. The site of pre puncture intubation had the history of surgery, trauma, radiotherapy or vascular malformation, occlusion and thrombosis.
4. Patients with NYHA >= 3, severe renal impairment (requiring renal replacement therapy), severe liver damage (child Pugh grade C), severe obstructive and restrictive pulmonary disease.

研究实施时间:

Study execute time:

From 2020-09-22 00:00:00 To 2022-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-09-22 00:00:00 To 2022-01-31 00:00:00  

干预措施:

Interventions:

组别:

干预组

样本量:

35

Group:

Intervention group

Sample size:

干预措施:

超声引导下颈浅丛神经阻滞

干预措施代码:

Intervention:

Ultrasound-guided superficial cervical plexus block

Intervention code:

组别:

对照组

样本量:

35

Group:

control group

Sample size:

干预措施:

局部麻醉

干预措施代码:

Intervention:

Regional anesthesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广西壮族自治区 

市(区县):

桂林市 

Country:

China 

Province:

Guangxi Zhuang Autonomous Region 

City:

Guilin 

单位(医院):

桂林医学院附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Guilin Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛评分

指标类型:

主要指标

Outcome:

Pain score

Type:

Primary indicator

测量时间点:

颈内静脉穿刺时、皮下隧道形成时、放置注射底座时、术后2小时、术后6小时

测量方法:

视觉模拟评分法

Measure time point of outcome:

Measure method:

Visual Analogue Scale

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

由未参与试验的研究人员采用随机数表法对患者进行分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients were divided into groups according to the random number table method by the researchers who were not involved in the trial.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开时间:试验完成后6个月内,网络平台:临床试验原始数据(IPD)共享平台:Resman, 网址:www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Time to open to the public:within 6 months after the trial was completed. ResMan reseach manager, website:www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有资料由研究方和申办方负责保存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All data including paper source record and CRF will be saved by investigator and sponsor

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-09-22 03:59:07